These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1451342)

  • 21. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
    Lubrich-Birkner I; Schollmeyer P; Steinhauer HB
    Adv Perit Dial; 1990; 6():302-7. PubMed ID: 1982833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route.
    Navarro JF; Teruel JL; Marcén R; Ortuño J
    Scand J Urol Nephrol; 1995 Mar; 29(1):11-4. PubMed ID: 7618043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
    Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
    Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure].
    Zheng FL; Bi ZQ; Li RS
    Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):440-3. PubMed ID: 8275819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients.
    Brown CD; Zhao ZH; Thomas LL; deGroof R; Friedman EA
    Am J Kidney Dis; 2001 Dec; 38(6):1414-20. PubMed ID: 11728984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is erythropoietin a survival factor for red blood cells?
    Polenakovic M; Sikole A
    J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction.
    Aufricht C; Marik JL; Ettenger RB
    Pediatr Nephrol; 1998 Jan; 12(1):10-3. PubMed ID: 9502558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
    Walter J; Gål J; Taraba I
    Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery.
    Sans T; Bofil C; Joven J; Clivillé X; Simó JM; Llobet X; Peró A; Galbany J
    Transfusion; 1996 Sep; 36(9):822-6. PubMed ID: 8823459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
    Besarab A; Golper TA
    ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proof-of-concept study on improved efficacy of rHuEPO administered as a long-term infusion in rats.
    Szczesny D; Mołoniewicz K; Markuszewski MJ; Wiczling P
    Pharmacol Rep; 2020 Oct; 72(5):1264-1270. PubMed ID: 32748255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
    Matsuhashi N; Yoshioka T
    Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.